MedTrace Logo

Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening

NCT06879834 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-03-17

No results posted yet for this study

Summary

To examine the potential for the detection of diabetic retinopathy (DR) using the artificial intelligence (AI)-based software platform Retina-AI.

Conditions

Interventions

DEVICE

taking fundus photos using non-mydriatic fundus camera

using artificial intelligence to identify diabetic retinopathy in the early stages using fundus photography.

Sponsors & Collaborators

  • CheckEye LLC

    collaborator INDUSTRY

  • Oftacentro SA

    collaborator OTHER

  • The Filatov Institute of Eye Diseases and Tissue Therapy

    lead OTHER

Principal Investigators

  • Andrii MD Korol, PhD · The Filatov Institute of Eye Diseases and Tissue Therapy

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-02
Primary Completion
2025-08-31
Completion
2025-12-31

Countries

  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06879834 on ClinicalTrials.gov